IP Library Granted Patent US 6,991,897
Granted Patent B2
US 6,991,897 · App. 10/632,377 · Granted Jan 31, 2006

Method of isolating stem cells

Assignee: Duke University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,991,897
App. No.
10/632,377
Granted
Jan 31, 2006
Kind
B2
Abstract

The present invention relates, in general, to stem cells, and in particular, to a method of isolating stem cells and to reagents suitable for use in such a method. The invention further relates to stem cell populations isolatable in accordance with the present method.

Claims (17)

1. A metbod for detecting the presence of stem cells in a population of cells comprising contacting said population of cells with a detectable substrate for aldehyde dehydrogenase (ALDH) under conditions such that ALDH present in cells of said population converts said substrate to a detectable product that is retained by said cells present in said population, wherein said stem cells have a higher concentration of said detectable product than non-stem cells present in said population wherein said substrate is BODIPY aminoacetaldehyde (BAAA).

2. The method according to claim 1 wherein said population of cells is a human population of cells.

3. The method according to claim 1 wherein said population of cells is derived from umbilical cord blood, bone marrow, peripheral blood or fetal liver.

4. The method according to claim 1 wherein efflux of said converted substrate from cells ofsaid population is inhibited by exposing said population of cells to a multiple drug resistance (MDR) inhibitor.

5. The method according to claim 4 wherein said MDR inhibitor is verapamil.

6. The method according to claim 4 wherein said MDR inhibitor is added to cells of said population simultaneously with or prior to addition of said substrate.

7. A method of detecting cells present in a population of cells that comprise an elevated level of ALDH comprising contacting said population of cells with a substrate for ALDH bearing a detectable label that is converted to a detectable product that is retained by cells of said population and determining which of said cells of said population have an elevated concentration or detectable product relative to other cells of said population, said cells of said population having said elevated concentration of detectable product being said cells having an elevated level of ALDH wherein said substrate is BODIPY aminoacetaldehyde (BAAA).

8. The method according to claim 7 wherein said cells of said population having an elevated level of ALDH are tumor cells.

9. A method of isolating stem cells present in a population of cells comprising contacting said population of cells with a detectable substrate for aldehyde dehydrogenase (ALDH) under conditions such that ALDH present in cells of said population converts said substrate to a detectable product that is retained by said cells present in said population, wherein said stern cells have a higher concentration of said detectable product than non-stem cells present in said population, and separating said stein cells from said non-stem cells of said population on the basis of said higher concentration of detectable product wherein said substrate is BODIPY aminoacetaldehyde (BAAA).

10. The method according to claim 9 wherein said population of cells is a human population of cells.

11. The method according to claim 9 wherein efflux of said converted substrate from said stem cells is inhibited by exposing said population or cells to a multiple drug resistance (MDR) inhibitor.

12. The method according to claim 11 wherein said MDR inhibitor is verapamil.

13. The method of claim 1 , wherein said population of cells is from a source selected from the group consisting of umbilical cord blood, bone marrow, peripheral blood and fetal liver.

14. The method of claim 13 , wherein said population of cells is from umbilical cord blood.

15. The method of claim 13 , wherein said population of cells is from bone marrow.

16. The method of claim 13 , wherein said population of cells is from peripheral blood.

17. The method of claim 13 , wherein said population of cells is from fetal liver.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 16, 2014
From: MIDCAP FUNDING III, LLC, AS AGENT
To: CYTOMEDIX, INC.; CYTOMEDIX ACQUISITION COMPANY, LLC; ALDAGEN, INC.
Reel/Frame 032684/0950 →
SECURITY INTEREST Recorded Apr 8, 2014
From: CYTOMEDIX, INC.; ALDAGEN, INC.; CYTOMEDIX ACQUISITION COMPANY, LLC
To: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; DEERFIELD SPECIAL SITUATIONS FUND, L.P.; DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.; DEERFIELD MGMT, L.P., AS AGENT
Reel/Frame 032629/0109 →
RELEASE OF SECURITY INTEREST Recorded Dec 28, 2007
From: INTERSOUTH AFFILIATES V, L.P.; AURORA ENRICHMENT FUND, LLC; INTERSOUTH PARTNERS V, L.P.; TALL OAKS STEMCO PARTNERS, LP; VILLAGE VENTURES PARTNERS FUND, L.P.; VILLAGE VENTURES PARTNERS FUND A, L.P.; CAUDILL, W. LOWRY; PIEDMONT ANGEL NETWORK LLC; CHILDERS, ALFRED G., MR.; THE TRELYS FUNDS, L.P.
To: ALDAGEN, INC. (FORMERLY, STEMCO BIOMEDICAL, INC.)
Reel/Frame 020288/0897 →
SECURITY AGREEMENT Recorded Apr 7, 2005
From: STEMCO BIOMEDICAL, INC.
To: CHILDERS, MR. ALFRED G.; THE TRELYS FUNDS, L.P.
Reel/Frame 015870/0686 →
SECURITY AGREEMENT Recorded Mar 28, 2005
From: STEMCO BIOMEDICAL, INC.
To: INTERSOUTH AFFILIATES V, L.P.; INTERSOUTH PARTNERS V, L.P.; AURORA ENRICHMENT FUND, LLC; TALL OAKS STEMCO PARTNERS, LP; VILLAGE VENTURES PARTNERS FUND, L.P.; VILLAGE VENTURES PARTNERS FUND A, L.P.; CAUDILL, W. LOWRY; PIEDMONT ANGEL NEWORK LLC
Reel/Frame 015829/0351 →
Continuity (3)
Division 0970141300
Provisional Application 6011119500 · Dec 7, 1998
Related Publication 20040023318A1 · Feb 5, 2004